Table I.
Group | Control | Diabetic | DM+fas |
---|---|---|---|
FBG (mmol/l) | 5.65±0.23 | 19.57±0.71a | 20.10±0.61a,b |
FINS (mU/l) | 33.95±2.51 | 52.53±5.47a | 47.08±2.90a,b |
HOMA-IR | 8.50±0.64 | 44.13±3.25a | 41.93±2.51a,b |
Differences among the three groups were assessed using one-way analysis of variance. The levels of FBG, FINS and HOMA-IR in the diabetic and the DM+fas groups were significantly increased compared to those in the control group, while no difference was identified between the diabetic group and the DM+fas group.
P<0.05 compared with the control group,
P>0.05 compared with the diabetic group. The number of rats in each group was six. Data are presented as the mean ± standard deviation.
DM+fas: diabetic rats treated with fasudil; FBG, fasting blood glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment for insulin resistance, calculated as FBG (mmol/l) x FINS (mU/l)/22.5.